Clinical Trials Arena on MSN
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability
MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...
"No answers. No medication. No follow-up call from my primary care physician. Just more pain, more confusion." ...
Researchers who have endometrosis themselves say they 'turned our pain into something positive for other women' ...
Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today announced that MIUDELLA® Hormone-Free Copper Intrauterine System (IUS) has been named to TIME's list of the best inventions of 2025.
Sebela’s Miudella is the first hormone-free IUD approved by the FDA in four decades and the first IUD to use nitinol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback